NASDAQ · HYPDHealthcarePharmaceuticals

Hyperion DeFi financials

$3.99+1.92%
Close Sep 29, 2026 · split-adjusted

Revenue

Net income

Income statement & cash flow

QuarterQ2 '26
Jun 30
Q1 '26
Mar 31
Q4 '25
Dec 31
Q3 '25
Sep 30
Revenue$357.7K$244.3K$496.2K$302.5K
Gross profit$357.7K$244.3K$193.0K$302.5K
Gross margin100.0%100.0%38.9%100.0%
Operating income$31.3M$5.2M-$39.2M$4.4M
Net income$14.3M$3.2M-$40.6M$1.6M
Net margin4009.1%1324.6%−8173.3%520.2%
Diluted EPS$0.92$0.26—$0.05
EBITDA$14.2M$6.4M-$18.3M$10.7M
Operating cash flow-$2.9M-$4.2M-$4.1M-$2.8M
Free cash flow-$2.9M-$4.2M-$4.1M-$2.8M
Diluted shares17.0M12.7M—29.0M

Balance sheet

Period endJun 30Mar 31Dec 31Sep 30
Cash & equivalents$9.6M$7.4M$6.3M$8.2M
Short-term investments$0.00$0.00$0.00$0.00
Total debt$8.4M$8.5M$7.8M$0.00
Total assets$113.1M$70.1M$51.8M$82.8M
Total liabilities$11.2M$11.6M$10.7M$12.0M
Shareholders' equity$101.9M$58.5M$41.1M$70.8M

From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology